All Programs

Use the tool below to view all available Global Cardiology Academy Series

Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
Cardiology
Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
- Ahmad Masri, MD, MS
DECAF Trial: Does Eliminating Coffee Reduce Atrial Fibrillation Recurrence in Symptomatic Patients?
DECAF Trial: Does Eliminating Coffee Reduce Atrial Fibrillation Recurrence in Symptomatic Patients?
Cardiology
DECAF Trial: Does Eliminating Coffee Reduce Atrial Fibrillation Recurrence in Symptomatic Patients?
- Christopher Wong
OCEAN Trial at AHA 2025: Anticoagulation After AF Ablation in High-Risk Patients
OCEAN Trial at AHA 2025: Anticoagulation After AF Ablation in High-Risk Patients
Cardiology
OCEAN Trial at AHA 2025: Anticoagulation After AF Ablation in High-Risk Patients
- Atul Verma, MD
POLY HF Trial: A Polypill Strategy for Heart Failure With Reduced Ejection Fraction (HFrEF)
POLY HF Trial: A Polypill Strategy for Heart Failure With Reduced Ejection Fraction (HFrEF)
Cardiology
POLY HF Trial: A Polypill Strategy for Heart Failure With Reduced Ejection Fraction (HFrEF)
- Ambarish Pandey, MD
ADAPT AF-DES: Antithrombotic Strategies Beyond 12 Months for Patients With AF Treated With Drug-Eluting-Stents
ADAPT AF-DES: Antithrombotic Strategies Beyond 12 Months for Patients With AF Treated With Drug-Eluting-Stents
Cardiology
ADAPT AF-DES: Antithrombotic Strategies Beyond 12 Months for Patients With AF Treated With Drug-Eluting-Stents
- Jung-Sun Kim, MD, PhD
Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
Nephrology
Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
- prof. Hiddo Heerspink
New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
Nephrology
New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
- prof. Hiddo Heerspink
The Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
The Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
Nephrology
The Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
- Rajiv Agarwal, MBBS, MD, FASN, BRCU
PREVENT vs PCE: Refining ASCVD Risk Prediction in Statin-Treated Populations
PREVENT vs PCE: Refining ASCVD Risk Prediction in Statin-Treated Populations
Heart Matters
PREVENT vs PCE: Refining ASCVD Risk Prediction in Statin-Treated Populations
The LDL-C Gap in Statin-Treated Patients: A Population-Level Problem with Economic Consequences
The LDL-C Gap in Statin-Treated Patients: A Population-Level Problem with Economic Consequences
Heart Matters
The LDL-C Gap in Statin-Treated Patients: A Population-Level Problem with Economic Consequences
Understanding Preload Deficiency in SLE: A New Look at Fatigue and Exercise Intolerance
Understanding Preload Deficiency in SLE: A New Look at Fatigue and Exercise Intolerance
Living Rheum
Understanding Preload Deficiency in SLE: A New Look at Fatigue and Exercise Intolerance
- Ryan Quigley
- Luigi Adamo, MD, PhD
- Andrea Fava, MD
MinuteCE®
Decoding Itch in CKD: From CKD-aP Suspicion to Solution
1.00 credit 9 episodes
- James Burton, DM, FRCP
- Leonie Kraft, MD
- Lucio Manenti, MD, PhD
- Emilio Sanchez, MD, PhD
1.00 credit 9 episodes
Optimizing Outcomes in Patients With oHCM: The Emerging Role of Cardiac Myosin Inhibitors
Optimizing Outcomes in Patients With oHCM: The Emerging Role of Cardiac Myosin Inhibitors
CME/CE Broadcast Replay
Optimizing Outcomes in Patients With oHCM: The Emerging Role of Cardiac Myosin Inhibitors
0.50 credits
- Iacopo Olivotto, MD
- Ahmad Masri, MD, MS
- Pablo Garcia-Pavia, MD, PhD
- Fabian Knebel, MD, PhD
- Caroline Coats, MD
0.50 credits
Understanding Lipid and Lipoprotein Metabolism in Cardiovascular Health
Understanding Lipid and Lipoprotein Metabolism in Cardiovascular Health
Heart Matters
Understanding Lipid and Lipoprotein Metabolism in Cardiovascular Health
Behind the Screens: Innovations in Type 1 Diabetes Clinical Trials—From Immunomodulation to Screening Strategies and Advanced Cell Therapies
Behind the Screens: Innovations in Type 1 Diabetes Clinical Trials—From Immunomodulation to Screening Strategies and Advanced Cell Therapies
CME/CE
Behind the Screens: Innovations in Type 1 Diabetes Clinical Trials—From Immunomodulation to Screening Strategies and Advanced Cell Therapies
- Irene Caruso
VICTOR Trial Results: Regional Variation in Outcomes and Response to Vericiguat in Patients With HFrEF
VICTOR Trial Results: Regional Variation in Outcomes and Response to Vericiguat in Patients With HFrEF
Cardiology
VICTOR Trial Results: Regional Variation in Outcomes and Response to Vericiguat in Patients With HFrEF
- Carolyn Lam, MD

All Programs

Popular

Title

Share on ReachMD

Welcome to Global Cardiology Academy

Welcome to Global
Cardiology Academy